Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 121

1.

Cost and cost-effectiveness of switching from stavudine to tenofovir in first-line antiretroviral regimens in South Africa.

Rosen S, Long L, Fox M, Sanne I.

J Acquir Immune Defic Syndr. 2008 Jul 1;48(3):334-44. doi: 10.1097/QAI.0b013e31817ae5ef.

PMID:
18545151
2.

Cost and cost-effectiveness of switching from d4T or AZT to a TDF-based first-line regimen in a resource-limited setting in rural Lesotho.

Jouquet G, Bygrave H, Kranzer K, Ford N, Gadot L, Lee J, Hilderbrand K, Goemaere E, Vlahakis N, Trivino L, Makakole L, Cleary S.

J Acquir Immune Defic Syndr. 2011 Nov 1;58(3):e68-74. doi: 10.1097/QAI.0b013e31822a9f8d.

PMID:
21765366
3.

Antiviral efficacy and genotypic resistance patterns of combination therapy with stavudine/tenofovir in highly active antiretroviral therapy experienced patients.

Antinori A, Trotta MP, Nasta P, Bini T, Bonora S, Castagna A, Zaccarelli M, Quirino T, Landonio S, Merli S, Tozzi V, Di Perri G, Andreoni M, Perno CF, Carosi G.

Antivir Ther. 2006;11(2):233-43.

PMID:
16640104
4.

The impact of reducing stavudine dose versus switching to tenofovir on plasma lipids, body composition and mitochondrial function in HIV-infected patients.

Milinkovic A, Martinez E, López S, de Lazzari E, Miró O, Vidal S, Blanco JL, Garrabou G, Laguno M, Arnaiz JA, Leon A, Larrousse M, Lonca M, Mallolas J, Gatell JM.

Antivir Ther. 2007;12(3):407-15.

PMID:
17591031
5.

The use of a triple nucleoside-nucleotide regimen for nonoccupational HIV post-exposure prophylaxis.

Winston A, McAllister J, Amin J, Cooper DA, Carr A.

HIV Med. 2005 May;6(3):191-7.

6.

Long-term renal safety of tenofovir disoproxil fumarate in antiretroviral-naive HIV-1-infected patients. Data from a double-blind randomized active-controlled multicentre study.

Izzedine H, Hulot JS, Vittecoq D, Gallant JE, Staszewski S, Launay-Vacher V, Cheng A, Deray G; Study 903 Team.

Nephrol Dial Transplant. 2005 Apr;20(4):743-6. Epub 2005 Mar 1.

PMID:
15741212
7.

The 3-year renal safety of a tenofovir disoproxil fumarate vs. a thymidine analogue-containing regimen in antiretroviral-naive patients.

Gallant JE, Winston JA, DeJesus E, Pozniak AL, Chen SS, Cheng AK, Enejosa JV.

AIDS. 2008 Oct 18;22(16):2155-63. doi: 10.1097/QAD.0b013e3283112b8e.

PMID:
18832879
8.

Cost-effectiveness of tenofovir instead of zidovudine for use in first-line antiretroviral therapy in settings without virological monitoring.

von Wyl V, Cambiano V, Jordan MR, Bertagnolio S, Miners A, Pillay D, Lundgren J, Phillips AN.

PLoS One. 2012;7(8):e42834. doi: 10.1371/journal.pone.0042834. Epub 2012 Aug 8.

9.

Rates of switching antiretroviral drugs in a primary care service in South Africa before and after introduction of tenofovir.

Njuguna C, Orrell C, Kaplan R, Bekker LG, Wood R, Lawn SD.

PLoS One. 2013 May 22;8(5):e63596. doi: 10.1371/journal.pone.0063596. Print 2013.

10.

Comparison of tenofovir, zidovudine, or stavudine as part of first-line antiretroviral therapy in a resource-limited-setting: a cohort study.

Velen K, Lewis JJ, Charalambous S, Grant AD, Churchyard GJ, Hoffmann CJ.

PLoS One. 2013 May 14;8(5):e64459. doi: 10.1371/journal.pone.0064459. Print 2013.

11.

Factors associated with the emergence of K65R in patients with HIV-1 infection treated with combination antiretroviral therapy containing tenofovir.

von Wyl V, Yerly S, Böni J, Bürgisser P, Klimkait T, Battegay M, Bernasconi E, Cavassini M, Furrer H, Hirschel B, Vernazza PL, Rickenbach M, Ledergerber B, Günthard HF; Swiss HIV Cohort Study.

Clin Infect Dis. 2008 Apr 15;46(8):1299-309. doi: 10.1086/528863.

12.

Effects of the change from Stavudine to tenofovir in human immunodeficiency virus-infected children treated with highly active antiretroviral therapy: studies on mitochondrial toxicity and thymic function.

Rosso R, Nasi M, Di Biagio A, Repetto E, Dentone C, Pinti M, Nemes E, Ferraresi R, Mussini C, Esposito R, Viscoli C, Cossarizza A.

Pediatr Infect Dis J. 2008 Jan;27(1):17-21.

PMID:
18162932
13.

Improvement of dyslipidemia during different HAART regimens: tenofovir- versus stavudine-containing antiretroviral combinations.

Manfredi R.

Clin Infect Dis. 2006 May 1;42(9):1345-7; author reply 1347-8. No abstract available.

PMID:
16586399
14.

[Cost effectiveness analysis of highly active antiretroviral therapy in HIV asymptomatic patients].

Pinto JL, López Lavid C, Badia X, Coma A, Benavides A.

Med Clin (Barc). 2000;114 Suppl 3:62-7. Spanish.

PMID:
10994566
15.

A 12-month treatment with tenofovir does not impair bone mineral accrual in HIV-infected children.

Giacomet V, Mora S, Martelli L, Merlo M, Sciannamblo M, Viganò A.

J Acquir Immune Defic Syndr. 2005 Dec 1;40(4):448-50.

PMID:
16280700
16.
17.

Serum hypophosphatemia in tenofovir disoproxil fumarate recipients is multifactorial in origin, questioning the utility of its monitoring in clinical practice.

Day SL, Leake Date HA, Bannister A, Hankins M, Fisher M.

J Acquir Immune Defic Syndr. 2005 Mar 1;38(3):301-4.

PMID:
15735448
18.

High prevalence of the K65R mutation in HIV-1 subtype C infected patients failing tenofovir-based first-line regimens in South Africa.

Skhosana L, Steegen K, Bronze M, Lukhwareni A, Letsoalo E, Papathanasopoulos MA, Carmona SC, Stevens WS.

PLoS One. 2015 Feb 6;10(2):e0118145. doi: 10.1371/journal.pone.0118145. eCollection 2015.

19.

Evaluation of hypophosphataemia in tenofovir disoproxil fumarate (TDF)-exposed and TDF-unexposed HIV-infected out-patients receiving highly active antiretroviral therapy.

Buchacz K, Brooks JT, Tong T, Moorman AC, Baker RK, Holmberg SD, Greenberg A; HIV Outpatient Study (HOPS) Investigators.

HIV Med. 2006 Oct;7(7):451-6.

20.

Tenofovir use is associated with an increase in serum alkaline phosphatase in the Swiss HIV Cohort Study.

Fux CA, Rauch A, Simcock M, Bucher HC, Hirschel B, Opravil M, Vernazza P, Cavassini M, Bernasconi E, Elzi L, Furrer H; Swiss HIV Cohort Study.

Antivir Ther. 2008;13(8):1077-82.

PMID:
19195333

Supplemental Content

Support Center